Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorPeking University People's Hospital
About this trial
This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.
Eligibility criteria
Qualifiers
Meet the American College of Rheumatology criteria for the diagnosis of SLE.
The test for plasma CMV DNA viral load is positive.
Age: 18 to 65 years, weight 45-80kg, male or female, gender ratio is not limited.
Apply corticosteroid less than 1.0mg/kg/d.
Disqualifiers
Inability to comply with IL-2 treatment regimen;
Other active infections. (hepatitis B or C virus, Epstein-Barr virus, human immunodeficiency virus, Mycobacterium tuberculosis or pneumocystis carinii pneumonia)
Any anti-CMV vaccine within 6 months;
History of intravenous immunoglobulin (IVIG) or leflunomide within 6 months prior to randomization, and those who have undergone plasmapheresis;
Trial design
Treatments tested in this trial
- Interleukin-2 (IL-2)
- Ganciclovir (GCV)
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov